

Efficacy and Safety of Vedolizumab for Pediatrics With Inflammatory Bowel Disease: a Systematic Review

Shengbo Fang

First Hospital of Jilin University

Yanqing Song

First Hospital of Jilin University

Chunyan Zhang

First Hospital of Jilin University

Libo Wang (✉ wanglib@jlu.edu.cn)

First Hospital of Jilin University

Research Article

Keywords: inflammatory bowel disease, vedolizumab, pediatrics, systematic review

Posted Date: November 12th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1022122/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at BMC Pediatrics on April 4th, 2022. See the published version at <https://doi.org/10.1186/s12887-022-03229-x>.

Abstract

Background: Vedolizumab use in pediatrics is still off-label and the data are limited. We conducted a systematic review evaluating the efficacy and safety of vedolizumab in children and adolescents with inflammatory bowel disease (IBD).

Methods: PubMed, EMBASE and Cochrane databases were systematically searched for studies of vedolizumab in children and adolescents with IBD reporting clinical remission, response, corticosteroid-free (CS-free) remission, mucosal healing, or safety up to November 21 2020.

Results: 7 studies, comprising 238 patients were included. For CD, the pooled clinical remission rates were 25% (19/75) at 6 weeks, 28% (19/67) at 14 weeks, 32% (17/53) at 22 weeks, and 25% (1/4) at 1 year. For UC/IBD-U, the pooled clinical remission rates were 36% (25/70) at 6 weeks, 52% (32/61) at 14 weeks, 53% (24/45) at 22 weeks, and 60% (6/10) at 1 year. Mucosal healing was found in 17%-39% of CD and 15%-34% of UC/IBD-U respectively. Six percent of patients reported serious adverse events.

Conclusions: According to low-quality evidence based on case series, approximately one-third and one-half of patients for CD and UC/IBD-U respectively achieved remission within 22 weeks. Long-term benefit profile data and high quality evidence are still needed.

Background

Medical therapies commonly used for inflammatory bowel disease (IBD) include aminosalicylates, corticosteroids, immune modifiers, biologic agents, antibiotics and probiotics [1]. As IBD relapse rate is high, some patients might become corticosteroid-dependent or corticosteroid-resistant. It is reported that the rate of steroid dependency is much higher in children than in adults (45% vs. 8% respectively) [2]. Besides, although anti-TNF agents have been a significant breakthrough in the treatment of IBD, approximately ~10%-40% patients do not improve after therapy (primary non-response), and ~20%-40% may lose response to therapy overtime (second loss of response) [3–7]. Therefore, there is still a great need for new drugs with other mechanisms of action that act on different inflammatory pathways involved in the pathogenesis of IBD [8].

Vedolizumab is a novel, fully humanized immunoglobulin G1 monoclonal antibody selective for the gut. It can block only $\alpha4\beta7$ integrin that inhibits adhesion of a gut-homing subset of T lymphocytes to mucosal addressing cellular adhesion molecule-1 (MAdCAM-1) [9]. For adults, the efficacy and safety of vedolizumab on moderate-to-severely active UC or CD have been established by GEMINI clinical trials [10–12], and got marketing approval in May 2014 in the USA and later in Europe [13–14]. Guidelines suggested vedolizumab could be in the treatment of UC where anti-TNF therapy had failed [15], and UC or CD who was refractory to steroids or anti-TNF [16–17]. For children, European Crohn's and Colitis Organization (ECCO) and European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) recommended vedolizumab for UC in chronically active or steroid-dependent patients as second line biologic therapy after anti-TNF failure [18], and for CD in patients who fail to achieve or maintain clinical remission on anti-TNF agents, despite anti-TNF dose optimization and immunomodulator use [19]. Nevertheless, vedolizumab use in pediatric population is still off-label and the efficacy evidence is insufficient. Given that the increasing use of vedolizumab in pediatrics, safety monitoring is essential, as it is suggested that drug safety must be demonstrated independently from adult studies and couldn't be extrapolated [20].

The aim of this study was to summarize the current evidence and to assess the efficacy and safety of vedolizumab for children and adolescents with IBD.

Methods

The systematic review was registered in PROSPERO (registration number: CRD42020222828) and was performed in accordance with the guidelines established by the PRISMA statement [21].

Literature search

We systematically searched PubMed, EMBASE and Cochrane Library databases from inception to November 21 2020 using the following search terms: "inflammatory bowel disease", "vedolizumab", "child" and "adolescent". The full search strategy is detailed in Supplementary Data (Table S1). Language or publication type was without restriction.

Inclusion criteria

Studies that met the following criteria were included in this systematic review: (a) studies carried out in children and adolescents with pediatric onset (< 18 years) IBD (CD, UC, unspecified), remaining under pediatric monitoring, and evaluation up to 21 years old were included; (b) treatment with vedolizumab alone or combination with other agents; (c) studies written in English

Exclusion criteria

Studies were excluded according to the following criteria: (a) studies on non-human subjects; (b) studies conducted on adults subjects; (c) the number of case series is less than five; (d) studies that were letters or editorial; (e) studies that lacked sufficient raw data; (f) studies that were duplicated; (g) studies that were ongoing or not finished; (h) abstract only.

Outcomes and endpoints

The primary outcome measure of this systematic review was clinical remission; second outcome measures included: (a) clinical response; (b) corticosteroid-free (CS-free) clinical remission; (c) mucosal healing; (d) safety (any adverse event that was judged related to vedolizumab by authors of the primary study).

Clinical remission, clinical response and CS-free rates were collected after first dose where available. The definition of clinical remission, clinical response, CS-free clinical remission and mucosal healing varied in different studies and were summarized in Table 1.

Table 1
Characteristics of included studies

Study characteristics			Outcome definitions		
First author[year]	Country	Design	Remission criteria (clinical remission or CS-free clinical remission)	Response criteria	Mucosal healing criteria
Singh[2016] ²⁵	USA	Retrospective case series	Clinical remission: PUCAI < 10 or wPCDAI < 12.5	NR	NR
Conrad[2016] ²⁶	USA	Prospective case series	Steroid-free remission: Inactive disease by PCDAI (≤ 10) or PUCAI (< 10) and no current corticosteroid therapy	PCDAI decrease ≥ 12.5 ; PUCAI decrease ≥ 20 ;	NR
Ledder[2017] ²⁷	Multi-country	Retrospective case series	Steroid-and exclusive enteral nutrition [EEN]-free remission: wPCDAI < 12.5 or PUCAI < 10 without the need for new medications or surgical intervention;	NR	SES-CD < 3 in CD or UCEIS = 0 in UC/IBD-U
Schneider[2018] ²⁸	Austria	Retrospective case series	Clinical remission: shPCDAI < 10 points; PUCAI < 10 points	NR	NR
Olbjørn[2020] ²⁹	Norway	Case series	NR	NR	NR
Jossen[2020] ³⁰	USA	Retrospective case series	CS-free clinical remission: PCDAI < 12.5, or partial Mayo score < 2 and off corticosteroids	NR	Endoscopic remission and Histologic remission: Endoscopic remission: Mayo Score = 0; SES-CD score ≤ 2 ; Histological remission: Nancy Index score ≤ 1 in UC and a CD histologic activity score ≤ 1 in every segment;
Dolinger[2020] ³¹	USA	Prospective case series	CS-free remission: wPCDAI ≤ 12.5 or pMS < 2, and no form of corticosteroids for at least 4 weeks.	NR	NR

Abbreviations: PCDAI, pediatric Crohn's disease activity index; wPCDAI, weighted pediatric Crohn's disease activity index; shPCDAI, short pediatric Crohn's disease activity index; PUCAI, pediatric ulcerative disease activity index; pMS, partial Mayo score; CS, corticosteroids; SES-CD, simple endoscopic score for Crohn's disease; UCEIS, ulcerative colitis endoscopic index of severity; CD, Crohn's disease; UC, ulcerative disease; IBD-U, inflammatory bowel disease unspecified; NR, not reported.

Data extraction

All the potentially related articles were retained by two authors (FSB, SYQ) independently, and the full texts were strictly reviewed according to inclusion/exclusion criteria regarding to preset outcomes. Any disagreements were resolved by consensus or consulted with a senior author (WLB). For the included studies, the following items were extracted: study characteristics (author, year of publication, country, study design), patients characteristics (age, type of IBD, disease behavior, percentage of anti-TNF experienced), vedolizumab dosage, clinical efficacy and adverse events (AEs).

Methodological assessment

For quality assessment, a validated quality appraisal tool developed by the Canadian Institute of Health Economics (IHE) was used for case series [22], including study objectives, population, interventions and co-interventions, outcome measures, statistical analysis, results and conclusions and competing interests. A study with 14 or more yes responses ($\geq 70\%$) was considered to be of acceptable quality [23]. The grade of evidence was showed in Table S2.

Statistical analysis

We provided descriptive statistics. Continuous parametric data are presented as mean and standard deviation (SD), while nonparametric data presented as median followed by range or interquartile range (IQR), unless otherwise specified. The categorical data of the outcome measures are expressed as percentage of total cases with 95% confidence interval (95% CI).

Results

Details of the search strategy are summarized in Figure 1. A total of 384 citations were identified through PubMed, EMBASE and Cochrane library, of which 363 were excluded, based on the title or abstract. Twenty-one citations were evaluated in more details. Of these, fourteen were excluded for various reasons (Figure 1), leaving 7 articles including a total of 238 patients (n=120 CD, n=118 UC/IBD-U) [24–30]. All studies focused on both CD and UC/IBD-U. 4 studies reported clinical remission rates [24–27]. 2 studies reported clinical response rates [25, 27]. 5 studies reported CS-free remission rates [24–27, 30] and 2 reported mucosal healing [26, 29]. 6 studies reported safety outcomes for CD or UC/IBD-U combined, rather than by separate indication [24–28, 30]. Characteristics of the included studies are listed in Table 1, and patient demographics were showed in Table 2. These studies were mostly reported by

institutions from the USA and differed with respect to patients' age, number of patients included, concomitant treatment, vedolizumab dose, duration of treatment and follow-up, and definition of outcomes.

Table 2
Baseline characteristics of the patients included in systematic review

Study ID	IBD type	Number of patients	Age years: median [range]/ Mean \pm SD	Baseline severity		Vedolizumab dose	Proportion of patients anti-TNF experienced	Concomitant medication	Disease behavior ^a
				PCDAI median [range]	PUCAI median [range]/pMS score median [range]				
Singh[2016] ²⁵	CD/UC	52	14.9(7-17)	32.5 (17.5–45)	30 (IQR 10–55)	300mg(n=39); 6mg/kg(n=11); 5mg/kg(n=2)	47/52	AZA/6-MP/MTX:15/52 CS:29/52	NR
Conrad[2016] ²⁶	CD/UC/IBD-U	21	13-18 (n=15); 19-21 (n=6)	25.0 (IQR 17.5–38.1)	30.0 (IQR 20.0–35.0)	300mg	21/21	AZA/6-MP:1/21 MTX:8/21 CS:15/21	B1 9/16 B2 3/16 B3 2/16 B2&B3 2/16 P 8/16
Ledder[2017] ²⁷	CD/UC/IBD-U	64	10.7 \pm 3.6	37.5 (IQR 24–61)	45 (IQR 30–65)	300mg(n=52); 150-250mg(3.6-10.3mg/kg) (n=12)	64/64	AZA/6-MP/MTX:21/64 CS:41/64	B1 17/23 B2 5/23 B3 1/23 P 4/23
Schneider[2018] ²⁸	CD/UC/IBD-U	12	15(8-17)	Median:47.5	Median:70	6mg/kg(Max 300mg)	12/12	CS:8/11 AZA:3/11 5-ASA:2/11	NR
Olbjørn[2020] ²⁹	CD/UC	8	17(14-17.5)	68.75(IQR 65-76.25)	67.5(IQR 55.63-73.75)	300mg	8/8	IFX:8/8	B1 2/4 B3 2/4 P 1/4
Jossen[2020] ³⁰	CD/UC	68	16.4(IQR 13.3-18.2)	Anti-TNF naïve:26.2 (IQR 19.4–35.6) Anti-TNF exposed: 35 (IQR 25-57.5)	pMS: Anti-TNF naïve: 3.5 (2–5) pMS: Anti-TNF exposed: 6 (3–6.5)	\geq 30kg:300mg 19-29kg:6-10mg/kg	36/68	CS:44/68	B1 29/33 B2 3/33 B3 1/33 P 10/33
Dolinger[2020] ³¹	CD/UC/IBD-U	13	15.9 (IQR 13.5–16.9)	58.75 (IQR 31.25–58.75)	pMS:4 (IQR 0–7)	300mg	13/13	NR	B1 6/7 B2 1/7

^a: Disease behavior classification was according to Paris classification

Abbreviations: IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative disease; IBD-U, inflammatory bowel disease unspecified; SD, standard deviation; IQR, interquartile range; PCDAI, Pediatric Crohn's Disease Activity Index; PUCAI, Pediatric Ulcerative Disease Activity Index; pMS, partial Mayo score; TNF, tumour necrosis factor; CS, corticosteroids; AZA, azathioprine; MP, 6-mercaptopurine; MTX, methotrexate; IFX, infliximab; 5-ASA, 5-aminosalicylic acid; B1, Nonstricturing; B2, Stricturing; B3, Penetrating; P, Perianal; NR = not reported.

Primary outcome

Clinical remission

In CD patients, the short-term clinical remission rate at 2 weeks of therapy ranged from 0–27% [two studies] [24, 27], and at 6 weeks of treatment ranged from 0–35% [four studies] [24–27]. For maintenance therapy, the remission rates were ranging from 17–42% at 14 weeks [four studies] [24–27], 24–39% at 22 weeks [three studies] [24–26], 73% at 30 weeks [one study] [24], and 25% at 1 year [one study] [26]. In UC/IBD-U patients, the short-term clinical remission rate

at 2 weeks of therapy ranged from 40–41% [two studies] [24, 27], and at 6 weeks of treatment ranged from 20–64% [four studies] [24–27]. During maintenance treatment, the remission rates were ranging from 20–77% at 14 weeks [four studies] [24–27], 40–71% at 22 weeks [three studies] [24–26], 75% at 30 weeks [one study] [24], and 60% at 1 year [one study] [26].

Secondary outcomes

CS-free clinical remission

The short-term CS-free clinical remission rates were 7% for CD [one study] [25] and 0% for UC/IBD-U [one study] [25] at 6 weeks respectively. For maintenance treatment, CS-free clinical remission rates in CD patients ranged from 0–19% at 14 weeks [three studies] [25–27], 13–33% at 22weeks [three studies] [24–26], 71% at 26 weeks [one study] [30], and 0% at 38 weeks [one study] [27]. In UC patients, CS-free clinical remission rates were ranging from 20–44% at 14 weeks [three studies] [25–27], 40–71% at 22 weeks [three studies] [24–26], 78% at 26 weeks [one study] [30], and 80% at 38 weeks [one study] [27].

Clinical response

In CD patients, clinical response rates were 33% at 6 weeks [one study] [25], ranging from 33–47% at 14 weeks [two studies] [25, 27], and 60% at 22 weeks [one study] [25]. In UC/IBD-U patients, clinical response rates were 20% at 2 weeks [one study] [27], 25% at 6 weeks [one study] [25], 75% at 14 weeks [one study] [25], and 50% at 22 weeks [one study] [25].

The pooled results for clinical remission rates, CS-free clinical remission, and response rates were presented in Table 3.

Table 3
Efficacy of Vedolizumab on pediatric inflammatory bowel disease

IBD type	Outcome measures	Number of studies	Overall [percentage; 95% CI]
CD	Remission		
	2 weeks	2	8/36[22;11-42]
	6 weeks	4	19/75[25;17-37]
	14 weeks	4	19/67[28;15-38]
	22 weeks	3	17/53[32;19-44]
	30 weeks	1	8/11[73;46-99]
	1 year	1	1/4[25;-17-67]
	Response		
	6 weeks	1	5/15[33;9-57]
	14 weeks	2	9/21[41;22-64]
	22 weeks	1	9/15[60;35-85]
	CS-free clinical remission		
	6 weeks	1	1/15[7;-6-19]
	14 weeks	3	5/37[14;3-29]
	22 weeks	3	12/47[26;11-36]
26 weeks	1	5/7[71;38-105]	
38 weeks	1	0/6[0;NA]	
UC/IBD-U	Remission		
	2 weeks	2	11/27[41;22-59]
	6 weeks	4	25/70[36;10-57]
	14 weeks	4	32/61[52;26-72]
	22 weeks	3	24/45[53;36-73]
	30 weeks	1	6/8[75;45-105]
	1 year	1	6/10[60;30-90]
	Response		
	2 weeks	1	1/5[20;-15-55]
	6 weeks	1	1/4[25;-17-67]
	14 weeks	1	3/4[75;33-117]
	22 weeks	1	2/4[50;1-99]
	CS-free clinical remission		
	6 weeks	1	0/5[0;NA]
	14 weeks	3	17/44[39;17-51]
22 weeks	3	26/45[58;44-73]	
26 weeks	1	7/9[78;51-105]	
38 weeks	1	4/5[80;45-115]	
Abbreviations: IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative disease; IBD-U, inflammatory bowel disease unspecified; CS, corticosteroids.			

Mucosal healing

Only two studies (87 patients in total) reported mucosal healing results [26, 29]. Mucosal healing was found in 17%-39% of CD (n=39) and 15%-34% of UC/IBD-U (n=48) respectively, with various evaluation time. Details of number of patients assessed and evaluation time were presented in Table 4.

Table 4
Summary of mucosal healing rate among patients with Crohn's disease or Ulcerative Colitis receiving vedolizumab

IBD type	Study	Patients with mucosal healing (n)	Patients assessed (n)	Rate (%)	Follow-up time(weeks):Median[IQR]
CD					
	Ledder[2017]	1	6	17	24[14-38]
	Jossen[2020]	13	33	39	49[32-73]
UC/IBD-U					
	Ledder[2017]	2	13	15	24[14-36]
	Jossen[2020]	12	35	34	49[32-73]
Abbreviations: IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative disease; IBD-U, inflammatory bowel disease unspecified					

Safety

6 studies (n=173) reported safety outcomes [24-28, 30]. Among them, one reported elevated transaminases and eczema which were considered unrelated to vedolizumab [28]; one studies didn't report number of patients who had AEs but reported number of AEs occurrence [25]. Serious AE rates were reported in 6 studies with 3 studies reporting zero [24, 26, 28] and the other 3 studies reporting 6.25%-38.1% [25, 27, 30]. The most common AEs were nausea and vomiting, and respiratory tract infection. Details were showed in Table 5.

Table 5
Adverse events during vedolizumab therapy

Any adverse events	No Reported Occurrences	Serious adverse events ^c	No Reported Occurrences
Overall	NR	Overall	10/173
Respiratory tract infection ^a	8	Dehydration/vomiting	4
Nausea and vomiting	9	Flare of disease ^d	3
Fatigue	4	Bowel-associated dermatosis–arthritis syndrome ^e	1
Skin infections	2	Synovitis, acne, pustulosis, hyperostosis, osteitis ^f	1
Headache	2	Obstructing nephrolithiasis and pyonephritis ^g	1
Erythema nodosum	2	Diverting ileostomy ^h	1
Allergic reaction ^b	2	Colectomy	1
Otitis externa	1	Severe systemic allergic reaction	1
Periorbital oedema	1	Septic arthritis ⁱ	1
Intractable itch	1	Deep vein thrombosis ^j	1
Dizziness	1		
New perianal disease	1		
Septic arthritis	1		
Deep vein thrombosis	1		
Abbreviations: NR, no exact number reported (Conrad et al [2016] didn't report number of patients who had adverse events)			
^a includes upper respiratory tract infection, nasopharyngitis, sinusitis			
^b includes mild shortness of breath and general systemic allergic reaction with dyspnoea			
^c includes requiring hospitalization or vedolizumab discontinued			
^d 3 patients developed new extraintestinal manifestations of IBD, of which 2 subjects had new onset erythema nodosum, and 1 subject developed bowel-associated dermatosis–arthritis syndrome.			
^e The subject who had diverting ileostomy due to severe perianal disease, developed bowel-associated dermatosis–arthritis syndrome and was treated with antibiotics and corticosteroids with subsequent resolution of symptoms and continued on vedolizumab without further recurrence of these manifestations.			
^f The subject who initially had erythema nodosum, later developed synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome, characterized by dermatologic and osteoarticular findings without clear etiology that has been associated with IBD in previous case reports.			
^g The subject with CD, who had a history of recurrent acute kidney injury due to hypovolemia with disease flares, developed obstructing nephrolithiasis with associated pyonephritis, then underwent drainage and ureteral stent placement as well as intravenous antibiotic treatment, and was continued on vedolizumab achieving remission without further kidney involvement.			
^h The subject with CD, who had worsening symptoms and distal colonic inflammation, required a diverting ileostomy.			
ⁱ The subject with UC treated with the combination of vedolizumab 300 mg every 8 weeks and tofacitinib 10 mg twice daily, in addition to prednisone 30 mg daily, developed septic arthritis of the right knee 2 months after dual therapy initiation, requiring inpatient hospitalization with incision and drainage and a prolonged course of intravenous antibiotic therapy.			
^j The subject above subsequently developed a deep vein thrombosis in the right leg 5 months after dual therapy initiation.			

Study quality

A 20-item validated quality appraisal tool for case series were used for quality assessment. The median of quality score was 18 (range 13-18), with only one study quality score less than 14. The grade of evidence was showed in Table S2.

Discussion

The results of this systematic review showed that most of the pediatric data on the effectiveness and safety of vedolizumab for the treatment of IBD were descriptive and the evidence were inadequate, as all the studies included were case series without randomized controlled trails (RCTs).

Overall, we found 0%-35% of CD patients achieved clinical remission in short-term therapy, compared to that of 20%-64% in UC patients. During maintenance therapy, 17%-73% of CD patients and 20%-77% of UC/IBD-U patients achieved clinical remission. Approximately one-third to one half of CD patients and 20%-75% of UC/IBD-U patients had clinical response with quite small sample size. These findings might suggest that lower therapeutic response was achieved in CD compared with UC, which was consistent with previously published studies in adults. Randomized controlled trials of GEMINI 1 and 2 found that compared with CD, the response and remission rates in UC were higher at both 6 weeks (47.1% and 16.9% vs. 31.4% and 14.5%) and 52 weeks (56.6% and 41.8% vs. 39.0% and 43.5%) [10, 11]. Canadian and Hungarian real-world cohorts also showed significantly greater clinical remission and response rate for UC compared with CD [31, 32]. However, opposite results reported by Gabriele et al, cohort in Italy showed better results for CD patients, with higher clinical response and remission rate compared with UC at 14 weeks (85% and 69% vs. 52% and 30%), 24 weeks (84% and 61% vs. 56% and 26%) and 52 weeks (59% and 45% vs. 25% and 20%) [33]. The difference in clinical response and remission rate could be attributed to quite small sample size and differences in patients baseline characteristics variability: the characteristic of patients involved varied in IBD phenotype, disease severity at vedolizumab initiation, disease duration.

Steroid-free remission, whether clinically or endoscopically is an important treatment goal for pediatric IBD [20, 34], as corticosteroids have potentially serious side effects associated with long term use including linear growth restriction, and osteopenia amongst many others [35]. In a meta-analysis on adult population, approximately one-quarter of CD or UC achieved CS-free clinical remission at 14 weeks, while 31% of CD and 42% of UC of that at 12 months [36]. Our study seemingly showed similar results. In our study, we found 0%-19% of CD and 20%-44% of UC/IBD-U patients achieved CS-free clinical remission at 14 weeks. Higher rate was identified for UC (40%-71%) compared with CD (13%-33%) at 22 weeks. However, opposite results existed. In a real-world study by Fabiana et al, better results for CD were identified at any follow-up time [ie, between 8-12 weeks 53.6% vs.18.7% (UC); 30 weeks 56.5% vs. 25% (UC); 52 weeks 53.6% vs. 35.4%(UC)], as much more CS ongoing UC were initially involved [45.8% vs. 24.6%(CD)] [37].

Although mucosal healing is a critical IBD therapy goal associated with sustained clinical remission, it is too burdensome for children to frequently undergo endoscopy. Therefore, only two studies of small sample size reported mucosal healing rates ranging from 17%-39% for CD and 15%-34% for UC/IBD-U with median follow-up time over 6 months. In addition, the definition of mucosal healing is still controversial. Most investigators agree that an endoscopic Mayo subscore of 0 for UC, and simple endoscopic score for Crohn's disease (SES-CD) 0-2 for CD [20]. However, one study involved in our review defined mucosal healing more strictly, including a composite of both endoscopic (macroscopic) and histologic indices [29]. In adult population, mucosal healing rates are reported as 21.2-41.9% for CD and 15%-57.1% for UC regardless of patients' baseline characteristics [31–33, 38].

Whether anti-TNF-experienced or not is the factor influencing the outcome of vedolizumab treatment has been disputed. Two post hoc analyses from the GEMINI studies assessed the efficacy of vedolizumab in CD and UC based on previously anti-TNF experienced patients [39, 40]. Results showed for CD, there were higher response and remission rates in patients who were anti-TNF-naïve compared with anti-TNF-experienced, and the advantages persisted to week 52 [39]. In UC patients, similar outcomes were found. Compared to placebo, patients naïve to anti-TNF had higher rates of response than patients with anti-TNF failure at week 6, whereas during maintenance therapy, there were no significant difference with placebo in both groups and between the two groups [40]. In contrast, however, some real-world clinical studies indicated that there was no impact of previous anti-TNF exposure on response or maintenance of remission though the sample size of TNF-naïve patients were small [31, 41]. Chaparro et al found the remission rates of patients who were anti-TNF naïve, with failure to 1 anti-TNF and failure to >1 anti-TNF at week 14 were 57.6%, 51.2% and 44% respectively [41]. And study by Kotze et al demonstrated that previous failure to anti-TNF agents was not associated with the efficacy of vedolizumab [31]. More interestingly, study by Mader showed previous treatment with anti-TNF agents was associated with a significantly lower efficacy of VDZ in UC but not in CD patients [42]. This might be attributed to longer disease duration for anti-TNF-experienced UC patients. In pediatric population, Jossen et al found higher rates of both endoscopic and histologic remission in anti-TNF-naïve patients compared to those who were anti-TNF-experienced (66% vs. 42%, 52% vs 33%, respectively) [29]. However, authors admitted these anti-TNF-naïve patients had slightly less severe disease at baseline compared with the anti-TNF-experienced patients. Therefore, this question deserves further investigation in the future.

With respect to safety, phase 2 and 3 trials showed a favorable safety profile of vedolizumab, with similar AEs incidence rate compared with placebo [43, 44]. Safety data from real-world cohort studies reported the total AE incidence rate was 23.6%, with infectious complication rate 7.8% [44]. In pre-marketing clinical trials, the most frequently reported AEs were respiratory tract infection [21.2/100 person-years (PYs)] and abdominal pain (12.1/100 PYs) [43, 44]. And real-world data showed respiratory tract infection (3.6%) and arthralgia (3.1%) were most common AEs [44]. Our findings were basically consistent with those from adult populations. The most prevalent AEs were respiratory tract infection and nausea and vomiting. Nevertheless, one study reported by Conrad et al reported 38% (8/21) experienced 12 serious adverse events that required hospitalization [25].

There are several limitations in our review. Initially, there was a significant heterogeneity in study design, including the threshold criteria of patients involved and definitions of remission, response and mucosal healing. Most studies used Pediatric Crohn's Disease Activity Index (PCDAI) or Pediatric Ulcerative Disease Activity Index (PUCAI), but weighted Pediatric Crohn's Disease Activity Index (wPCDAI), short Pediatric Crohn's Disease Activity Index (shPCDAI) or partial Mayo score were also used. As to mucosal healing, endoscopic assessment alone was agreed by majority of investigators, but Jossen et al also evaluated histological changes [29]. Moreover, all the studies included were case series, some reported the data prospectively while the others used a retrospective approach, which may result in significant differences in clinical decision. In addition, there was no placebo-controlled trial with a standard protocol, which meant the effectiveness was not necessarily attributed to the intervention. The recurrent nature of CD additionally weakens the assessment of causal relationships between interventions and outcomes. Nevertheless, vedolizumab for pediatric patients is usually applied to patients with severe disease or those who are refractory to conventional therapies, which are unlikely to have spontaneous relief.

In spite of the above-mentioned shortcomings, we performed a comprehensive literature search. Although no RCTs were included, case series of vedolizumab therapy seemed to represent 'real-world' experience of pediatric population in different areas and medical centers and provide a deeper understanding of vedolizumab in heterogenous and more complex patient populations. Besides, the role of case series evidence in systematic reviews of health care

interventions is especially suitable for reviews of rapidly developing pharmacological interventions and supporting evidence on safety, when case series are usually the only available clinical evidence [45].

Conclusions

Based on low-quality evidence provided by case series, approximately one-third and one-half of patients for CD and UC/IBD-U respectively, achieved remission within 22 weeks with favorable safety profile. Long-term benefit profile data and more robust evidence are still needed.

Abbreviations

AEs: Adverse events; CD: Crohn's disease; CI: Confidence interval; CS: Corticosteroid; ECCO: European Crohn's and Colitis Organization; ESPGHAN: European Society for Pediatric Gastroenterology Hepatology and Nutrition; IBD: Inflammatory bowel disease; IBD-U: Inflammatory bowel disease-unspecified; IHE: Institute of Health Economics; IQR: Interquartile range; MAdCAM-1: Mucosal addressing cellular adhesion molecule-1; PCDAL: Pediatric Crohn's Disease Activity Index; PUCAI: Pediatric Ulcerative Disease Activity Index; RCTs: Randomized controlled trials; SD: Standard deviation; SES-CD: Simple endoscopic score for Crohn's disease; shPCDAI: short Pediatric Crohn's Disease Activity Index; UC: Ulcerative colitis; wPCDAI: weighted Pediatric Crohn's Disease Activity Index

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

All data used during the study are available from the corresponding author by request.

Competing interests

The authors declare that they have no competing interests

Funding

There is no funding support.

Authors' contributions

Shengbo Fang and Yanqing Song performed screening of papers, data extraction, quality assessment, collected and analyzed the data. Shengbo Fang and Chunyan Zhang wrote and revised the manuscript. Shengbo Fang performed the literature search. Libo Wang developed the study concept and protocol, leading role of coordinating the project, senior authorship to resolve disagreements on inclusion, exclusion and quality assessment of papers and critiquing and editing the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Acknowledgements

Thanks for Professor Ying kit Leung who assisted with editorial assistance.

References

1. Bernstein C, Eliakim A, Fedail S, Fried M, Geary R, Goh K, Hamid S, Khan A, Khalif I, Ng S *et al*: World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. *Journal of clinical gastroenterology* 2016, 50(10):803-818.
2. Jakobsen C, Bartek J, Wewer V, Vind I, Munkholm P, Groen R, Pærregaard A: Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease—a population-based study. *Alimentary pharmacology & therapeutics* 2011, 34(10):1217-1224.
3. Ford A, Sandborn W, Khan K, Hanauer S, Talley N, Moayyedi P: Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. *The American journal of gastroenterology* 2011, 106(4):644-659, quiz 660.
4. Sprakes M, Ford A, Warren L, Greer D, Hamlin J: Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. *Journal of Crohn's & colitis* 2012, 6(2):143-153.
5. Roda G, Jharap B, Neeraj N, Colombel J: Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. *Clinical and translational gastroenterology* 2016, 7:e135.
6. Ben-Horin S, Chowhry Y: Review article: loss of response to anti-TNF treatments in Crohn's disease. *Alimentary pharmacology & therapeutics* 2011, 33(9):987-995.
7. Papamichael K, Gils A, Rutgeerts P, Levesque B, Vermeire S, Sandborn W, Vande Casteele N: Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. *Inflammatory bowel diseases* 2015, 21(1):182-197.

8. Danese S: New therapies for inflammatory bowel disease: from the bench to the bedside. *Gut* 2012, 61(6):918-932.
9. Lamb C, O'Byrne S, Keir M, Butcher E: Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. *Journal of Crohn's & colitis* 2018, 12:S653-S668.
10. Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W, Van Assche G, Axler J, Kim H, Danese S *et al*: Vedolizumab as induction and maintenance therapy for ulcerative colitis. *The New England journal of medicine* 2013, 369(8):699-710.
11. Sandborn W, Feagan B, Rutgeerts P, Hanauer S, Colombel J, Sands B, Lukas M, Fedorak R, Lee S, Bressler B *et al*: Vedolizumab as induction and maintenance therapy for Crohn's disease. *The New England journal of medicine* 2013, 369(8):711-721.
12. Sands B, Feagan B, Rutgeerts P, Colombel J, Sandborn W, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M *et al*: Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology* 2014, 147(3):618-627.e613.
13. ENTYVIO® [Summary of Product Characteristics]. Taastrup, Denmark: Takeda Pharma A/S; 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002782/WC500168528.pdf. Accessed September 20, 2017.
14. ENTYVIO® [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; 2018. <https://general.takeda-pharm.com/ENTYVIOPI>. Accessed May 14, 2018.
15. Lamb C, Kennedy N, Raine T, Hendy P, Smith P, Limdi J, Hayee B, Lomer M, Parkes G, Selinger C *et al*: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019, 68:s1-s106.
16. Gomollón F, Dignass A, Annesse V, Tilg H, Van Assche G, Lindsay J, Peyrin-Biroulet L, Cullen G, Daperno M, Kucharzik T *et al*: 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. *Journal of Crohn's & colitis* 2017, 11(1):3-25.
17. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S *et al*: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. *Journal of Crohn's & colitis* 2017, 11(7):769-784.
18. Turner D, Ruemmele F, Orlanski-Meyer E, Griffiths A, de Carpi J, Bronsky J, Veres G, Aloï M, Strisciuglio C, Braegger C *et al*: Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *Journal of pediatric gastroenterology and nutrition* 2018, 67(2):257-291.
19. van Rheenen P, Aloï M, Assa A, Bronsky J, Escher J, Fagerberg U, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P *et al*: The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. *Journal of Crohn's & colitis* 2020.
20. Turner D, Griffiths A, Wilson D, Mould D, Baldassano R, Russell R, Dubinsky M, Heyman M, de Ridder L, Hyams J *et al*: Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. *Gut* 2020, 69(1):32-41.
21. Moher D, Liberati A, Tetzlaff J, Altman D: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine* 2009, 151(4):264-269, W264.
22. Guo B, Moga C, Harstall C, Schopflocher D: A principal component analysis is conducted for a case series quality appraisal checklist. *Journal of clinical epidemiology* 2016, 69:199-207.e192.
23. Moga C, Guo B, Schopflocher D, Harstall C. Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique. Edmonton AB: Institute of Health Economics, 2012.
24. Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, Phan BL, Hyams JS, Dubinsky MC: Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2016, 22(9):2121-2126.
25. Conrad MA, Stein RE, Maxwell EC, Albenberg L, Baldassano RN, Dawany N, Grossman AB, Mamula P, Piccoli DA, Kelsen JR: Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease. *Aliment Pharmacol Ther* 2016, 22(10):2425-2431.
26. Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A *et al*: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. *J Crohns Colitis* 2017, 11(10):1230-1237.
27. Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J: Vedolizumab use after failure of TNF- α antagonists in children and adolescents with inflammatory bowel disease. *BMC gastroenterology* 2018, 18(1):140.
28. Olbjørn C, Rove JB, Jahnsen J: Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. *Paediatric drugs* 2020, 22(4):409-416.
29. Jossen J, Kiernan BD, Pittman N, Dubinsky MC: Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease. *Journal of pediatric gastroenterology and nutrition* 2020, 70(3):304-309.
30. Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC: Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease. *Inflammatory bowel diseases* 2020.
31. Kotze P, Ma C, Almutairdi A, Al-Darmaki A, Devlin S, Kaplan G, Seow C, Novak K, Lu C, Ferraz J *et al*: Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. *Alimentary pharmacology & therapeutics* 2018, 48(6):626-637.
32. Bor R, Fábíán A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K *et al*: Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study. *Expert opinion on biological therapy* 2020, 20(2):205-213.
33. Dragoni G, Bagnoli S, Le Grazie M, Campani C, Rogai F, Manetti N, Bensi C, Macrì G, Galli A, Milla M: Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center. *Journal of digestive diseases* 2019, 20(5):235-242.
34. Ruemmele F, Hyams J, Otley A, Griffiths A, Kolho K, Dias J, Levine A, Escher J, Taminiau J, Veres G *et al*: Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. *Gut* 2015, 64(3):438-446.

35. Baldwin K, Kaplan J: Medical management of pediatric inflammatory bowel disease. *Seminars in pediatric surgery* 2017, 26(6):360-366.
36. Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid J, Loftus E: Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. *Journal of gastroenterology* 2018, 53(9):1048-1064.
37. Zingone F, Barberio B, Compostella F, Girardin G, D'Inca R, Marinelli C, Marsilio I, Lorenzon G, Savarino E: Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. *Therapeutic advances in gastroenterology* 2020, 13:1756284820936536.
38. Macaluso F, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S *et al*: Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. *United European gastroenterology journal* 2020, 8(9):1045-1055.
39. Sands B, Sandborn W, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K: Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. *Inflammatory bowel diseases* 2017, 23(1):97-106.
40. Feagan B, Rubin D, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M: Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2017, 15(2):229-239.e225.
41. Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A *et al*: Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. *Alimentary pharmacology & therapeutics* 2018, 48(8):839-851.
42. Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F: Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. *United European gastroenterology journal* 2020:2050640620965106.
43. Colombel J, Sands B, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus E, Sankoh S, Fox I *et al*: The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut* 2017, 66(5):839-851.
44. Bye W, Jairath V, Travis S: Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. *Alimentary pharmacology & therapeutics* 2017, 46(1):3-15.
45. Chambers D, Rodgers M, Woolacott N: Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. *Journal of clinical epidemiology* 2009, 62(12):1253-1260.e1254.

Figures




Figure 1

Flow chart of systematic review.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [PRISMA2009checklist.doc](#)
- [SupplementaryData.doc](#)